Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
unknown
📅 Published: 2026-01-02 12:44
📰 Source: Yahoo
📝 Words: 21
📝 Article Content
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
📄 Summary
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-01-09 00:08:12
Updated At:
2026-01-09 00:08:12
Scraping Job ID:
N/A
Stock Mentions:
ABBV - AbbVie Inc.
Relevance: N/A
NOW - ServiceNow Inc.
Relevance: N/A